Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1984 Nov 24;289(6456):1402–1404. doi: 10.1136/bmj.289.6456.1402

Scandinavian model for eliminating measles, mumps, and rubella.

E Rabo, J Taranger
PMCID: PMC1443676  PMID: 6437574

Full text

PDF
1402

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balfour H. H., Jr, Amren D. P. Rubella, measles and mumps antibodies following vaccination of children. A potential rubella problem. Am J Dis Child. 1978 Jun;132(6):573–577. doi: 10.1001/archpedi.1978.02120310037006. [DOI] [PubMed] [Google Scholar]
  2. Bjorvatn B., Sköldenberg B. Parotitmeningit och -orkit i Stockholm--en epidemiologisk bakgrund till vaccinationspolicy. Lakartidningen. 1978 Jun 7;75(23):2295–2298. [PubMed] [Google Scholar]
  3. Brunell P. A., Weigle K., Murphy M. D., Shehab Z., Cobb E. Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA. 1983 Sep 16;250(11):1409–1412. [PubMed] [Google Scholar]
  4. Böttiger M. Vaccination mot rubella. Lakartidningen. 1979 Oct 10;76(41):3516–3518. [PubMed] [Google Scholar]
  5. Cherry J. D. The 'new' epidemiology of measles and rubella. Hosp Pract. 1980 Jul;15(7):49–57. doi: 10.1080/21548331.1980.11946629. [DOI] [PubMed] [Google Scholar]
  6. Hinman A. R., Bart K. J., Orenstein W. A., Preblud S. R. Rational strategy for rubella vaccination. Lancet. 1983 Jan 1;1(8314-5):39–40. doi: 10.1016/s0140-6736(83)91572-6. [DOI] [PubMed] [Google Scholar]
  7. Jespersen C. S., Lttauer J., Sagild U. Measles as a cause of fetal defects. A retrospective study of tem measles epidemics in Greenland. Acta Paediatr Scand. 1977 May;66(3):367–372. doi: 10.1111/j.1651-2227.1977.tb07909.x. [DOI] [PubMed] [Google Scholar]
  8. Knox E. G. Strategy for rubella vaccination. Int J Epidemiol. 1980 Mar;9(1):13–23. doi: 10.1093/ije/9.1.13. [DOI] [PubMed] [Google Scholar]
  9. Krugman S. Further-attenuated measles vaccine: characteristics and use. Rev Infect Dis. 1983 May-Jun;5(3):477–481. doi: 10.1093/clinids/5.3.477. [DOI] [PubMed] [Google Scholar]
  10. Miller C. L. Current impact of measles in the United Kingdom. Rev Infect Dis. 1983 May-Jun;5(3):427–432. doi: 10.1093/clinids/5.3.427. [DOI] [PubMed] [Google Scholar]
  11. Murray M. J., Murray A., Murray C. J. The salutary effect of milk on amoebiasis and its reversal by iron. Br Med J. 1980 Jun 7;280(6228):1351–1352. doi: 10.1136/bmj.280.6228.1351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. O'Shea S., Best J. M., Banatvala J. E., Marshall W. C., Dudgeon J. A. Persistence of rubella antibody 8-18 years after vaccination. Br Med J (Clin Res Ed) 1984 Apr 7;288(6423):1043–1043. doi: 10.1136/bmj.288.6423.1043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Polk B. F., White J. A., DeGirolami P. C., Modlin J. F. An outbreak of rubella among hospital personnel. N Engl J Med. 1980 Sep 4;303(10):541–545. doi: 10.1056/NEJM198009043031001. [DOI] [PubMed] [Google Scholar]
  14. Rubella immunisation: whose baby? Br Med J (Clin Res Ed) 1984 Feb 18;288(6416):564–565. doi: 10.1136/bmj.288.6416.564-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sejda J. Control of measles in Czechoslovakia (CSSR). Rev Infect Dis. 1983 May-Jun;5(3):564–567. doi: 10.1093/clinids/5.3.564. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES